To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

Cost and committee reports

Official records Congress.gov attaches to H.R. 5850.

• Constitutional authority statementThe sponsor’s statement of where the Constitution gives Congress the power to pass this bill. Statement by Mr. MANN, as printed in the Congressional Record (Vol. 169, No. 159, September 29, 2023, Page H4911):
  Congress has the power to enact this legislation pursuant to the following--Article 1, Section 8 of the U.S. Constitution. The single subject of this legislation is: To prohibit the use of federal funds for implementing REMS for Mifepristone and to nullify the January 2023 REMS modifications for mifepristone.
  Source: Congress.gov, Congressional Record September 29, 2023 ↗

  Evidence

  Field in the Congress.gov record

  constitutionalAuthorityStatementText

  Statement length

  310 characters

  Congress.gov bill record

  H.R. 5850, 118th Congress

  Congress.gov API record

  https://api.congress.gov/v3/bill/118/hr/5850

  Record last updated by Congress.gov

  July 24, 2024

  PORKER copy retrieved

  September 14, 2026

  Stored copy, SHA-256 of the file

  ae73626ef931f12560d6676f5196fb3b92a612c39d315f88ba1a826ea8441c97

  PORKER shows the statement exactly as printed, with the page markup removed. It is the sponsor’s claim; it is not a legal finding.

Congress.gov’s record for this bill does not list a CBO cost estimate or a committee report (as of July 24, 2024). Not every bill gets one.

From the Congress.gov bill record for H.R. 5850, last updated July 24, 2024. PORKER’s copy was retrieved September 14, 2026 and is refreshed nightly. Open “Evidence” on any line for the record, field and file fingerprint.